From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy

Seminars in Cancer Biology

Volumn 46, Issue , 2017, Pages 65-83

  Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Artemisia annua; Artemisinin; Cancer; Chemotherapy; Drug repurposing; Malaria; Phytotherapy; Qinhaosu

Indexed keywords

ARTEETHER; ARTEMETHER; ARTEMISIA ANNUA EXTRACT; ARTEMISININ; ARTESUNATE; BETA CATENIN; BICALUTAMIDE; CISPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DIHYDROARTEMISININ; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAX PROTEIN; MYC PROTEIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TEMOZOLOMIDE; TRANSCRIPTION FACTOR AP 1; VINORELBINE TARTRATE; WNT PROTEIN; ARTEMISININ DERIVATIVE; TUMOR PROTEIN;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER INHIBITION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CELL DEATH; CELL ONCOSIS; DNA DAMAGE; DNA END JOINING REPAIR; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXCISION REPAIR; FERROPTOSIS; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; HEADACHE; HOMOLOGOUS RECOMBINATION; HUMAN; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LARYNX SQUAMOUS CELL CARCINOMA; LIVER CELL CARCINOMA; LONGITUDINAL STUDY; NECROPTOSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UTERINE CERVIX CANCER; ARTEMISIA ANNUA; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM;

ARTEMISIA ANNUA; ARTEMISININS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; OXIDATIVE STRESS;

EID: 85014219821     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2017.02.009     Document Type: Review

References (259)

1. Tu, Y.Y., Ni, M.Y., Zhong, Y.R., Li, L.N., Cui, S.L., Zhang, M.Q., et al. Studies on the constituents of Artemisia annua L. (author's transl). Yao Xue Xue Bao 16 (1981), 366–370.
2. Tu, Y.Y., The constituents of young Artemisia annua. Zhong Yao Tong Bao 10 (1985), 35–36 18.
3. Tu, Y., The development of the antimalarial drugs with new type of chemical structure?qinghaosu and dihydroqinghaosu. Southeast Asian J. Trop. Med. Public Health 35 (2004), 250–251.
4. Jeremic, D., Jokic, A., Behbud, A., Stefanovic, M., New type of sesquiterpene lactones isolated from Artemisia annua L. arteannuin B. Tetrahedron Lett. 14 (1973), 3039–3042.
5. Visser, B.J., Wieten, R.W., Kroon, D., Nagel, I.M., Belard, S., van Vugt, M., et al. Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar. J., 13, 2014, 463.
6. Isba, R., Zani, B., Gathu, M., Sinclair, D., Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst. Rev., 2, 2015, CD011547.
7. Naing, C., Whittaker, M.A., Mak, J.W., Aung, K., A systematic review of the efficacy of a single dose artemisinin-naphthoquine in treating uncomplicated malaria. Malar. J., 14, 2015, 392.
8. WWARN, Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med., 13, 2015, 227.
9. WWARN, Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Med., 13, 2015, 212.
10. Shayo, A., Buza, J., Ishengoma, D.S., Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania. Malar. J., 14, 2015, 135.
11. Yakasai, A.M., Hamza, M., Dalhat, M.M., Bello, M., Gadanya, M.A., Yaqub, Z.M., et al. Adherence to artemisinin-Based combination therapy for the treatment of uncomplicated malaria: a systematic review and meta-Analysis. J. Trop. Med., 2015, 2015, 189232.
12. Miller, L.H., Su, X., Artemisinin: discovery from the Chinese herbal garden. Cell 146 (2011), 855–858.
13. Neill, U.S., From branch to bedside: youyou Tu is awarded the 2011 Lasker ∼ DeBakey Clinical Medical Research Award for discovering artemisinin as a treatment for malaria. J. Clin. Invest. 121 (2011), 3768–3773.
14. Tu, Y., The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 17 (2011), 1217–1220.
15. Efferth, T., Zacchino, S., Georgiev, M.I., Liu, L., Wagner, H., Panossian, A., Nobel Prize for artemisinin brings phytotherapy into the spotlight. Phytomedicine 22 (2015), A1–3.
16. Ginsburg, H., Atamna, H., The redox status of malaria-infected erythrocytes: an overview with an emphasis on unresolved problems. Parasite 1 (1994), 5–13.
17. Shenai, B.R., Sijwali, P.S., Singh, A., Rosenthal, P.J., Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J. Biol. Chem. 275 (2000), 29000–29010.
18. Posner, G.H., Cumming, J.N., Ployprodith, P., Oh CH. Evidence for Fe(IV)jO in the molecular mechanism of action of the trioxane antimalarial artemisinin. J. Am. Chem. Soc. 117 (1995), 5885–5886.
19. Cumming, J.N., Ploypradith, P., Posner, G.H., Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Adv. Pharmacol. 37 (1997), 253–297.
20. O'Neill, P.M., Posner, G.H., A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. 47 (2004), 2945–2964.
21. Pandey, A.V., Tekwani, B.L., Singh, R.L., Chauhan, V.S., Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J. Biol. Chem. 274 (1999), 19383–19388.
22. Haynes, R.K., Cheu, K.W., Li, K.Y., Tang, M.M., Wong, H.N., Chen, M.J., et al. A partial convergence in action of methylene blue and artemisinins: antagonism with chloroquine, a reversal with verapamil, and an insight into the antimalarial activity of chloroquine. ChemMedChem 6 (2011), 1603–1615.
23. Shandilya, A., Chacko, S., Jayaram, B., Ghosh, I., A plausible mechanism for the antimalarial activity of artemisinin: a computational approach. Sci. Rep., 3, 2013, 2513.
24. Lisewski, A.M., Quiros, J.P., Ng, C.L., Adikesavan, A.K., Miura, K., Putluri, N., et al. Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate. Cell 158 (2014), 916–928.
25. Bhisutthibhan, J., Meshnick, S.R., Immunoprecipitation of [(3)H]dihydroartemisinin translationally controlled tumor protein (TCTP) adducts from Plasmodium falciparum-infected erythrocytes by using anti-TCTP antibodies. Antimicrob. Agents Chemother. 45 (2001), 2397–2399.
26. Eckstein-Ludwig, U., Webb, R.J., Van Goethem, I.D., East, J.M., Lee, A.G., Kimura, M., et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424 (2003), 957–961.
27. Parapini, S., Basilico, N., Mondani, M., Olliaro, P., Taramelli, D., Monti, D., Evidence that haem iron in the malaria parasite is not needed for the antimalarial effects of artemisinin. FEBS Lett. 575 (2004), 91–94.
28. Li, W.D., Dong, Y.J., Tu, Y.Y., Lin, Z.B., Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation. Int. Immunopharmacol. 6 (2006), 1243–1250.
29. Liu, R., Dong, H.F., Guo, Y., Zhao, Q.P., Jiang MS: Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasit. Vectors, 4, 2011, 201.
30. Ho, W.E., Peh, H.Y., Chan, T.K., Wong, W.S., Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol. Ther. 142 (2014), 126–139.
31. Efferth, T., Romero, M.R., Wolf, D.G., Stamminger, T., Marin, J.J., Marschall, M., The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 47 (2008), 804–811.
32. Jiang, W., Cen, Y., Song, Y., Li, P., Qin, R., Liu, C., Zhao, Y., Zheng, J., Zhou, H., Artesunate attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through inhibition of pro-inflammatory cytokines and pro-inflammatory chemokines. Phytomedicine 23 (2016), 1259–1266.
33. Woerdenbag, H.J., Moskal, T.A., Pras, N., Malingre, T.M., el-Feraly, F.S., Kampinga, H.H., et al. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J. Nat. Prod. 56 (1993), 849–856.
34. Lai, H., Singh, N.P., Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. 91 (1995), 41–46.
35. Efferth, T., Rücker, G., Falkenberg, M., Manns, D., Olbrich, A., Fabry, U., et al. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung 46 (1996), 196–200.
36. Zheng, G.Q., Cytotoxic terpenoids and flavonoids from Artemisia annua. Planta Med. 60 (1994), 54–57.
37. Beekman, A.C., Wierenga, P.K., Woerdenbag, H.J., Van Uden, W., Pras, N., Konings, A.W., et al. Artemisinin-derived sesquiterpene lactones as potential antitumour compounds: cytotoxic action against bone marrow and tumour cells. Planta Med. 64 (1998), 615–619.
38. Eteng, M.U., Abolaji, A.O., Ebong, P.E., Brisibe, E.A., Dar, A., Kabir, N., et al. Biochemical and haematological evaluation of repeated dose exposure of male Wistar rats to an ethanolic extract of Artemisia annua. Phytother. Res. 27 (2013), 602–609.
39. Li, J., Casteels, T., Frogne, T., Ingvorsen, C., Honore, C., Courtney, M., et al. Artemisinins target GABAA receptor signaling and impair alpha cell identity. Cell 168 (2017), 86–100.
40. Efferth, T., Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat. 8 (2005), 85–97.
41. Efferth, T., Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 7 (2006), 407–421.
42. Efferth, T., Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin?from bench to bedside. Planta Med. 73 (2007), 299–309.
43. Efferth, T., Li, P.C., Konkimalla, V.S., Kaina, B., From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 13 (2007), 353–361.
44. Seo, E.J., Wiench, B., Hamm, R., Paulsen, M., Zu, Y., Fu, Y., et al. Cytotoxicity of natural products and derivatives toward MCF-7 cell monolayers and cancer stem-like mammospheres. Phytomedicine 22 (2015), 438–443.
45. Subedi, A., Futamura, Y., Nishi, M., Ryo, A., Watanabe, N., Osada, H., High-throughput screening identifies artesunate as selective inhibitor of cancer stemness: involvement of mitochondrial metabolism. Biochem. Biophys. Res. Commun. 477 (2016), 737–742.
46. Chen, H.H., Zhou, H.J., Wu, G.D., Lou, X.E., Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology 71 (2004), 1–9.
47. Dell'Eva, R., Pfeffer, U., Vene, R., Anfosso, L., Forlani, A., Albini, A., et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharmacol. 68 (2004), 2359–2366.
48. Disbrow, G.L., Baege, A.C., Kierpiec, K.A., Yuan, H., Centeno, J.A., Thibodeaux, C.A., et al. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res. 65 (2005), 10854–10861.
49. Li, L.N., Zhang, H.D., Yuan, S.J., Tian, Z.Y., Wang, L., Sun, Z.X., Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int. J. Cancer 121 (2007), 1360–1365.
50. Hou, J., Wang, D., Zhang, R., Wang, H., Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res. 14 (2008), 5519–5530.
51. Chen, H., Sun, B., Pan, S., Jiang, H., Sun, X., Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 20 (2009), 131–140.
52. Du, J.H., Zhang, H.D., Ma, Z.J., Ji, K.M., Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother. Pharmacol. 65 (2010), 895–902.
53. Lai, H., Nakase, I., Lacoste, E., Singh, N.P., Sasaki, T., Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res. 29 (2009), 3807–3810.
54. Wu, Z.P., Gao, C.W., Wu, Y.G., Zhu, Q.S., Yan, C., Xin, L., et al. Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. Integr. Cancer Ther. 8 (2009), 88–92.
55. Bachmeier, B., Fichtner, I., Killian, P.H., Kronski, E., Pfeffer, U., Efferth, T., Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. PLoS One, 6, 2011, e20550.
56. Farsam, V., Hassan, Z.M., Zavaran-Hosseini, A., Noori, S., Mahdavi, M., Ranjbar, M., Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo. Int. Immunopharmacol. 11 (2011), 1802–1808.
57. Gao, N., Budhraja, A., Cheng, S., Liu, E.H., Huang, C., Chen, J., et al. Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. Apoptosis 16 (2011), 511–523.
58. Philips, G.M., Chan, I.S., Swiderska, M., Schroder, V.T., Guy, C., Karaca, G.F., et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One, 6, 2011, e23943.
59. Tin, A.S., Sundar, S.N., Tran, K.Q., Park, A.H., Poindexter, K.M., Firestone, G.L., Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anticancer Drugs 23 (2012), 370–379.
60. Wu, B., Hu, K., Li, S., Zhu, J., Gu, L., Shen, H., et al. Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer. Oncol. Rep. 27 (2012), 101–108.
61. Zhang, C.Z., Zhang, H., Yun, J., Chen, G.G., Lai, P.B., Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem. Pharmacol. 83 (2012), 1278–1289.
62. Liu, Y., Wang, W., Xu, J., Li, L., Dong, Q., Shi, Q., et al. Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/beta-catenin signaling. Oncol. Rep. 30 (2013), 1723–1730.
63. Sun, H., Meng, X., Han, J., Zhang, Z., Wang, B., Bai, X., et al. Anti-cancer activity of DHA on gastric cancer–an in vitro and in vivo study. Tumour Biol. 34 (2013), 3791–3800.
64. Zhou, X., Sun, W.J., Wang, W.M., Chen, K., Zheng, J.H., Lu, M.D., et al. Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo. Anticancer Drugs 24 (2013), 920–927.
65. Tilaoui, M., Mouse, H.A., Jaafari, A., Zyad, A., Differential effect of artemisinin against cancer cell lines. Nat. Prod. Bioprospect. 4 (2014), 189–196.
66. Vandewynckel, Y.P., Laukens, D., Geerts, A., Vanhove, C., Descamps, B., Colle, I., et al. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. Eur. J. Gastroenterol. Hepatol. 26 (2014), 861–870.
67. Zhu, H., Liao, S.D., Shi, J.J., Chang, L.L., Tong, Y.G., Cao, J., et al. DJ-1 mediates the resistance of cancer cells to dihydroartemisinin through reactive oxygen species removal. Free Radic. Biol. Med. 71 (2014), 121–132.
68. Zuo, W., Wang, Z.Z., Xue, J., Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression. Int. J. Mol. Sci. 15 (2014), 14298–14312.
69. Drenberg, C.D., Buaboonnam, J., Orwick, S.J., Hu, S., Li, L., Fan, Y., et al. Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemother. Pharmacol. 77 (2016), 1231–1243.
70. Ilamathi, M., Prabu, P.C., Ayyappa, K.A., Sivaramakrishnan, V., Artesunate obliterates experimental hepatocellular carcinoma in rats through suppression of IL-6-JAK-STAT signalling. Biomed. Pharmacother. 82 (2016), 72–79.
71. Jia, J., Qin, Y., Zhang, L., Guo, C., Wang, Y., Yue, X., et al. Artemisinin inhibits gallbladder cancer cell lines through triggering cell cycle arrest and apoptosis. Mol. Med. Rep. 13 (2016), 4461–4468.
72. Jia, L., Song, Q., Zhou, C., Li, X., Pi, L., Ma, X., et al. Dihydroartemisinin as a putative STAT3 inhibitor, suppresses the growth of head and neck squamous cell carcinoma by targeting Jak2/STAT3 signaling. PLoS One, 11, 2016, e0147157.
73. Lemke, D., Pledl, H.W., Zorn, M., Jugold, M., Green, E., Blaes, J., et al. Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. Oncotarget, 2016.
74. Li, Y., Wang, Y., Kong, R., Xue, D., Pan, S., Chen, H., et al. Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network. Oncotarget, 2016.
75. Roh, J.L., Kim, E.H., Jang, H., Shin, D., Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 11 (2016), 254–262.
76. Tong, Y., Liu, Y., Zheng, H., Zheng, L., Liu, W., Wu, J., et al. Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/beta-catenin signaling. Oncotarget 7 (2016), 31413–31428.
77. Greenshields, A.L., Shepherd, T.G., Hoskin, D.W., Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol. Carcinog. 56 (2017), 75–93.
78. Zhang, S., Shi, L., Ma, H., Li, H., Li, Y., Lu, Y., Wang, Q., Li, W., Dihydroartemisinin induces apoptosis in human gastric cancer cell line BGC-823 through activation of JNK1/2 and p38 MAPK signaling pathways. J. Recept. Signal Transduct. Res. 12 (2016), 1–7.
79. Liu, L., Zuo, L.F., Zuo, J., Wang, J., Artesunate induces apoptosis and inhibits growth of Eca109 and Ec9706 human esophageal cancer cell lines in vitro and in vivo. Mol. Med. Rep. 12 (2015), 1465–1472.
80. Feng, M.X., Hong, J.X., Wang, Q., Fan, Y.Y., Yuan, C.T., Lei, X.H., et al. Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts. Sci. Rep., 6, 2016, 19074.
81. Efferth, T., Olbrich, A., Bauer, R., mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol. 64 (2002), 617–623.
82. Efferth, T., Sauerbrey, A., Olbrich, A., Gebhart, E., Rauch, P., Weber, H.O., et al. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 64 (2003), 382–394.
83. Efferth, T., Oesch, F., Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem. Pharmacol. 68 (2004), 3–10.
84. Efferth, T., Volm, M., Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In Vivo 19 (2005), 225–232.
85. Efferth, T., Briehl, M.M., Tome, M.E., Role of antioxidant genes for the activity of artesunate against tumor cells. Int. J. Oncol. 23 (2003), 1231–1235.
86. Efferth, T., Giaisi, M., Merling, A., Krammer, P.H., Li-Weber, M., Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One, 2, 2007, e693.
87. Sieber, S., Gdynia, G., Roth, W., Bonavida, B., Efferth, T., Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. Int. J. Oncol. 35 (2009), 149–158.
88. Lu, Y.Y., Chen, T.S., Wang, X.P., Li, L., Single-cell analysis of dihydroartemisinin-induced apoptosis through reactive oxygen species-mediated caspase-8 activation and mitochondrial pathway in ASTC-a-1 cells using fluorescence imaging techniques. J. Biomed. Opt., 15, 2010, 046028.
89. Gao, X., Luo, Z., Xiang, T., Wang, K., Li, J., Wang, P., Dihydroartemisinin induces endoplasmic reticulum stress-mediated apoptosis in HepG2 human hepatoma cells. Tumori 97 (2011), 771–780.
90. Cabello, C.M., Lamore, S.D., Bair, W.B. 3rd, Qiao, S., Azimian, S., Lesson, J.L., et al. The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. Invest. New Drugs 30 (2012), 1289–1301.
91. Kong, R., Jia, G., Cheng, Z.X., Wang, Y.W., Mu, M., Wang, S.J., et al. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. PLoS One, 7, 2012, e37222.
92. Wang, Z., Hu, W., Zhang, J.L., Wu, X.H., Zhou, H.J., Dihydroartemisinin induces autophagy and inhibits the growth of iron-loaded human myeloid leukemia K562 cells via ROS toxicity. FEBS Open Bio 2 (2012), 103–112.
93. Zhou, C., Pan, W., Wang, X.P., Chen, T.S., Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. J. Cell. Physiol. 227 (2012), 3778–3786.
94. Gao, W., Xiao, F., Wang, X., Chen, T., Artemisinin induces A549 cell apoptosis dominantly via a reactive oxygen species-mediated amplification activation loop among caspase-9, −8 and −3. Apoptosis 18 (2013), 1201–1213.
95. Ganguli, A., Choudhury, D., Datta, S., Bhattacharya, S., Chakrabarti, G., Inhibition of autophagy by chloroquine potentiates synergistically anti-cancer property of artemisinin by promoting ROS dependent apoptosis. Biochimie 107 (2014), 338–349 (Pt B).
96. Jia, G., Kong, R., Ma, Z.B., Han, B., Wang, Y.W., Pan, S.H., et al. The activation of c-Jun NH(2)-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells. J. Exp. Clin. Cancer Res., 33, 2014, 8.
97. Lu, M., Sun, L., Zhou, J., Yang, J., Dihydroartemisinin induces apoptosis in colorectal cancer cells through the mitochondria-dependent pathway. Tumour Biol. 35 (2014), 5307–5314.
98. Noori, S., Hassan, Z.M., Farsam, V., Artemisinin as a Chinese medicine, selectively induces apoptosis in pancreatic tumor cell line. Chin. J. Integr. Med. 20 (2014), 618–623.
99. Papanikolaou, X., Johnson, S., Garg, T., Tian, E., Tytarenko, R., Zhang, Q., et al. Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis. Oncotarget 5 (2014), 4118–4128.
100. Beccafico, S., Morozzi, G., Marchetti, M.C., Riccardi, C., Sidoni, A., Donato, R., et al. Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells. Carcinogenesis 36 (2015), 1071–1083.
101. Gerhardt, T., Jones, R., Park, J., Lu, R., Chan, H.W., Fang, Q., et al. Effects of antioxidants and pro-oxidants on cytotoxicity of dihydroartemisinin to Molt-4 human leukemia cells. Anticancer Res. 35 (2015), 1867–1871.
102. Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A., Brady, N.R., Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2 (2015), 517–532.
103. Moore, J.C., Lai, H., Li, J.R., Ren, R.L., McDougall, J.A., Singh, N.P., et al. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett. 98 (1995), 83–87.
104. Singh, N.P., Lai, H., Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 70 (2001), 49–56.
105. Efferth, T., Benakis, A., Romero, M.R., Tomicic, M., Rauh, R., Steinbach, D., et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med. 37 (2004), 998–1009.
106. Kelter, G., Steinbach, D., Konkimalla, V.B., Tahara, T., Taketani, S., Fiebig, H.H., et al. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One, 2, 2007, e798.
107. Zhang, C., Zhang, F., Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell 6 (2015), 88–100.
108. Singh, N.P., Lai, H.C., Artemisinin induces apoptosis in human cancer cells. Anticancer Res. 24 (2004), 2277–2280.
109. Lai, H., Sasaki, T., Singh, N.P., Messay, A., Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci. 76 (2005), 1267–1279.
110. Lai, H., Sasaki, T., Singh, N.P., Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds. Expert Opin. Ther. Targets 9 (2005), 995–1007.
111. Lu, J.J., Meng, L.H., Cai, Y.J., Chen, Q., Tong, L.J., Lin, L.P., et al. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol. Ther. 7 (2008), 1017–1023.
112. Nakase, I., Gallis, B., Takatani-Nakase, T., Oh, S., Lacoste, E., Singh, N.P., et al. Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett. 274 (2009), 290–298.
113. Zhang, S., Gerhard, G.S., Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. PLoS One, 4, 2009, e7472.
114. Hamacher-Brady, A., Stein, H.A., Turschner, S., Toegel, I., Mora, R., Jennewein, N., et al. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J. Biol. Chem. 286 (2011), 6587–6601.
115. Lu, J.J., Chen, S.M., Zhang, X.W., Ding, J., Meng, L.H., The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest. New Drugs 29 (2011), 1276–1283.
116. Mercer, A.E., Copple, I.M., Maggs, J.L., O'Neill, P.M., Park, B.K., The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J. Biol. Chem. 286 (2011), 987–996.
117. Ba, Q., Zhou, N., Duan, J., Chen, T., Hao, M., Yang, X., et al. Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1. PLoS One, 7, 2012, e42703.
118. Blazquez, A.G., Fernandez-Dolon, M., Sanchez-Vicente, L., Maestre, A.D., Gomez-San Miguel AB, Alvarez M, et al: novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. Bioorg. Med. Chem. 21 (2013), 4432–4441.
119. Chan, H.W., Singh, N.P., Lai, H.C., Cytotoxicity of dihydroartemisinin toward Molt-4 cells attenuated by N-tert-butyl-alpha-phenylnitrone and deferoxamine. Anticancer Res. 33 (2013), 4389–4393.
120. Zhao, F., Wang, H., Kunda, P., Chen, X., Liu, Q.L., Liu, T., Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71. Oncol. Rep. 30 (2013), 1473–1482.
121. Chikazawa, S., Kitahara, Y., Ando, E., Hori, Y., Hoshi, F., Kanai, K., et al. Erythrophagocytosis enhances heme-dependent cytotoxicity of antimalarial drugs in canine histiocytic sarcoma cell line DH82. J. Vet. Med. Sci. 76 (2014), 249–253.
122. Yang, Y., Zhang, X., Wang, X., Zhao, X., Ren, T., Wang, F., et al. Enhanced delivery of artemisinin and its analogues to cancer cells by their adducts with human serum transferrin. Int. J. Pharm. 467 (2014), 113–122.
123. Jeong DE SH, Lim S., Lee, S.J., Lim, J.E., Nam, D.H., Joo, K.M., Jeong, B.C., Jeon, S.S., Choi, H.Y., Lee, H.W., Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget 6 (2015), 33046–33064.
124. Ooko, E., Saeed, M.E., Kadioglu, O., Sarvi, S., Colak, M., Elmasaoudi, K., et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 22 (2015), 1045–1054.
125. Wang, Q., Wu, S., Zhao, X., Zhao, C., Zhao, H., Huo, L., Mechanisms of dihydroartemisinin and Dihydroartemisinin/Holotransferrin cytotoxicity in T-Cell lymphoma cells. PLoS One, 10, 2015, e0137331.
126. Kim, S.H., Kang, S.H., Kang, B.S., Therapeutic effects of dihydroartemisinin and transferrin against glioblastoma. Nutr. Res. Pract. 10 (2016), 393–397.
127. Cao, J.Y., Dixon, S.J., Mechanisms of ferroptosis. Cell. Mol. Life Sci. 73 (2016), 2195–2209.
128. Lin, R., Zhang, Z., Chen, L., Zhou, Y., Zou, P., Feng, C., et al. Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells. Cancer Lett. 381 (2016), 165–175.
129. Aulbert, E., Disselhoff, W., Sorje, H., Schulz, E., Gericke, D., Lysosomal accumulation of 67Ga–transferrin in malignant tumors in relation to their growth rate. Eur. J. Cancer 16 (1980), 1217–1232.
130. Shterman, N., Kupfer, B., Moroz, C., Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiology 59 (1991), 19–25.
131. Gatter, K.C., Brown, G., Trowbridge, I.S., Woolston, R.E., Mason, D.Y., Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 36 (1983), 539–545.
132. Judd, W., Poodry, C.A., Strominger, J.L., Novel surface antigen expressed on dividing cells but absent from nondividing cells. J. Exp. Med. 152 (1980), 1430–1435.
133. Trowbridge, I.S., Omary, M.B., Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc. Natl. Acad. Sci. U. S. A. 78 (1981), 3039–3043.
134. Sutherland, R., Delia, D., Schneider, C., Newman, R., Kemshead, J., Greaves, M., Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Acad. Sci. U. S. A. 78 (1981), 4515–4519.
135. Li, P.C., Lam, E., Roos, W.P., Zdzienicka, M.Z., Kaina, B., Efferth, T., Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res. 68 (2008), 4347–4351.
136. Berdelle, N., Nikolova, T., Quiros, S., Efferth, T., Kaina, B., Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol. Cancer Ther. 10 (2011), 2224–2233.
137. Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H., Chitambar, C.R., The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 18 (2001), 767–773.
138. Alcantara, D.D., Ribeiro, H.F., Cardoso, P.C., Araujo, T.M., Burbano, R.R., Guimaraes, A.C., et al. In vitro evaluation of the cytotoxic and genotoxic effects of artemether, an antimalarial drug, in a gastric cancer cell line (PG100). J. Appl. Toxicol. 33 (2013), 151–156.
139. Aquino, I., Tsuboy, M.S., Marcarini, J.C., Mantovani, M.S., Perazzo, F.F., Maistro, E.L., Genotoxic evaluation of the antimalarial drugs artemisinin and artesunate in human HepG2 cells and effects on CASP3 and SOD1 gene expressions. Genet. Mol. Res. 12 (2013), 2517–2527.
140. Park, J., Lai, H.C., Sasaki, T., Singh, N.P., DNA damage in dihydroartemisinin-resistant Molt-4 cells. Anticancer. Res. 35 (2015), 1339–1343.
141. Wang, B., Hou, D., Liu, Q., Wu, T., Guo, H., Zhang, X., et al. Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol. Ther. 16 (2015), 1548–1556.
142. Jiao, Y., Ge, C.M., Meng, Q.H., Cao, J.P., Tong, J., Fan, S.J., Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol. Sin. 28 (2007), 1045–1056.
143. Chen, H., Sun, B., Wang, S., Pan, S., Gao, Y., Bai, X., et al. Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. J. Cancer Res. Clin. Oncol. 136 (2010), 897–903.
144. Li, S., Xue, F., Cheng, Z., Yang, X., Wang, S., Geng, F., et al. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. Int. J. Hematol. 90 (2009), 513–521.
145. Willoughby, J.A. Sr., Sundar, S.N., Cheung, M., Tin, A.S., Modiano, J., Firestone, G.L., Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J. Biol. Chem. 284 (2009), 2203–2213.
146. Horwedel, C., Tsogoeva, S.B., Wei, S., Efferth, T., Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells. J. Med. Chem. 53 (2010), 4842–4848.
147. Steinbrück, L., Pereira, G., Efferth T.v Effects of artesunate on cytokinesis and G(2)/M cell cycle progression of tumour cells and budding yeast. Cancer Genomics Proteomics 7 (2010), 337–346.
148. Ji, Y., Zhang, Y.C., Pei, L.B., Shi, L.L., Yan, J.L., Ma, X.H., Anti-tumor effects of dihydroartemisinin on human osteosarcoma. Mol. Cell Biochem. 351 (2011), 99–108.
149. Wu, J., Hu, D., Yang, G., Zhou, J., Yang, C., Gao, Y., et al. Down-regulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells. J. Cell. Biochem. 112 (2011), 1938–1948.
150. Jiang, Z., Chai, J., Chuang, H.H., Li, S., Wang, T., Cheng, Y., et al. Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells. Anticancer Drugs 23 (2012), 606–613.
151. Mao, Z.G., Zhou, J., Wang, H., He, D.S., Xiao, W.W., Liao, G.Z., et al. Artesunate inhibits cell proliferation and decreases growth hormone synthesis and secretion in GH3 cells. Mol. Biol. Rep. 39 (2012), 6227–6234.
152. Du, X.X., Li, Y.J., Wu, C.L., Zhou, J.H., Han, Y., Sui, H., et al. Initiation of apoptosis, cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin. Biomed. Pharmacother. 67 (2013), 417–424.
153. Mao, H., Gu, H., Qu, X., Sun, J., Song, B., Gao, W., et al. Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. Int. J. Mol. Med. 31 (2013), 213–218.
154. Cao, L., Duanmu, W., Yin, Y., Zhou, Z., Ge, H., Chen, T., et al. Dihydroartemisinin exhibits anti-glioma stem cell activity through inhibiting p-AKT and activating caspase-3. Pharmazie 69 (2014), 752–758.
155. Chen, K., Shou, L.M., Lin, F., Duan, W.M., Wu, M.Y., Xie, X., et al. Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. Anticancer Drugs 25 (2014), 652–662.
156. Tran, K.Q., Tin, A.S., Firestone, G.L., Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-kappaB transcriptional signaling. Anticancer Drugs 25 (2014), 270–281.
157. Zhang, H.T., Wang, Y.L., Zhang, J., Zhang, Q.X., Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53. Tumour Biol. 35 (2014), 1403–1409.
158. Zhu, S., Liu, W., Ke, X., Li, J., Hu, R., Cui, H., et al. Artemisinin reduces cell proliferation and induces apoptosis in neuroblastoma. Oncol. Rep. 32 (2014), 1094–1100.
159. Shi, R., Cui, H., Bi, Y., Huang, X., Song, B., Cheng, C., et al. Artesunate altered cellular mechanical properties leading to deregulation of cell proliferation and migration in esophageal squamous cell carcinoma. Oncol Lett. 9 (2015), 2249–2255.
160. Huang, Z., Huang, X., Jiang, D., Zhang, Y., Huang, B., Luo, G., Dihydroartemisinin inhibits cell proliferation by induced G1 arrest and apoptosis in human nasopharyngealcarcinoma cells. J. Cancer Res. Ther. 12 (2016), 244–247.
161. Sundar, S.N., Marconett, C.N., Doan, V.B., Willoughby, J.A. Sr., Firestone, G.L., Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells. Carcinogenesis 29 (2008), 2252–2258.
162. Hargraves, K.G., He, L., Firestone, G.L., Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells. Mol. Carcinog. 55 (2016), 486–498.
163. Yamachika, E., Habte, T., Oda, D., Artemisinin: an alternative treatment for oral squamous cell carcinoma. Anticancer Res. 24 (2004), 2153–2160.
164. Huang, X.J., Ma, Z.Q., Zhang, W.P., Lu, Y.B., Wei, E.Q., Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J. Pharm. Pharmacol. 59 (2007), 849–856.
165. Mu, D., Chen, W., Yu, B., Zhang, C., Zhang, Y., Qi, H., Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells. Methods Find Exp. Clin. Pharmacol. 29 (2007), 33–38.
166. Mu, D., Zhang, W., Chu, D., Liu, T., Xie, Y., Fu, E., et al. The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. Cancer Chemother. Pharmacol. 61 (2008), 639–645.
167. Hosoya, K., Murahari, S., Laio, A., London, C.A., Couto, C.G., Kisseberth, W.C., Biological activity of dihydroartemisinin in canine osteosarcoma cell lines. Am. J. Vet. Res. 69 (2008), 519–526.
168. Ramacher, M., Umansky, V., Efferth, T., Effect of artesunate on immune cells in ret-transgenic mouse melanoma model. Anticancer Drugs 20 (2009), 910–917.
169. Youns, M., Efferth, T., Reichling, J., Fellenberg, K., Bauer, A., Hoheisel, J.D., Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. Biochem. Pharmacol. 78 (2009), 273–283.
170. Zhou, H.J., Zhang, J.L., Li, A., Wang, Z., Lou, X.E., Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. Cancer Chemother. Pharmacol. 66 (2010), 21–29.
171. Handrick, R., Ontikatze, T., Bauer, K.D., Freier, F., Rubel, A., Durig, J., et al. Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol. Cancer Ther. 9 (2010), 2497–2510.
172. He, Q., Shi, J., Shen, X.L., An, J., Sun, H., Wang, L., et al. Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biol. Ther. 9 (2010), 819–824.
173. Michaelis, M., Kleinschmidt, M.C., Barth, S., Rothweiler, F., Geiler, J., Breitling, R., et al. Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem. Pharmacol. 79 (2010), 130–136.
174. Aung, W., Sogawa, C., Furukawa, T., Saga, T., Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor model evaluated by conventional methods and optical imaging. Anticancer Res. 31 (2011), 1549–1558.
175. Thanaketpaisarn, O., Waiwut, P., Sakurai, H., Saiki, I., Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-kappaB and PI3 K/Akt signaling pathways. Int. J. Oncol. 39 (2011), 279–285.
176. Chen, M., Chen, T.S., Lu, Y.Y., Liu, C.Y., Qu, J.L., Dihydroarteminsin-induced apoptosis is not dependent on the translocation of Bim to the endoplasmic reticulum in human lung adenocarcinoma cells. Pathol. Oncol. Res. 18 (2012), 809–816.
177. Lu, J.J., Chen, S.M., Ding, J., Meng, L.H., Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line. Mol. Cell Biochem. 360 (2012), 329–337.
178. Holien, T., Olsen, O.E., Misund, K., Hella, H., Waage, A., Ro, T.B., et al. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate. Eur. J. Haematol. 91 (2013), 339–346.
179. Lee, J., Shen, P., Zhang, G., Wu, X., Zhang, X., Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib. Biomed. Pharmacother. 67 (2013), 157–163.
180. Hu, C.J., Zhou, L., Cai, Y., Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2. Cancer Biol. Ther. 15 (2014), 279–288.
181. Odaka, Y., Xu, B., Luo, Y., Shen, T., Shang, C., Wu, Y., et al. Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells. Carcinogenesis 35 (2014), 192–200.
182. Mondal, A., Chatterji, U., Artemisinin represses telomerase subunits and induces apoptosis in HPV-39 infected human cervical cancer cells. J. Cell Biochem. 116 (2015), 1968–1981.
183. Qin, G., Zhao, C., Zhang, L., Liu, H., Quan, Y., Chai, L., et al. Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells. Apoptosis 20 (2015), 1072–1086.
184. Lian, S., Shi, R., Huang, X., Hu, X., Song, B., Bai, Y., et al. Artesunate attenuates glioma proliferation, migration and invasion by affecting cellular mechanical properties. Oncol. Rep. 36 (2016), 984–990.
185. Tang, C., Ao, P.Y., Zhao, Y.Q., Huang, S.Z., Jin, Y., Liu, J.J., et al. Effect and mechanism of dihydroartemisinin on proliferation, metastasis and apoptosis of human osteosarcoma cells. J. Biol. Regul. Homeost. Agents 29 (2015), 881–887.
186. Xu, N., Zhou, X., Wang, S., Xu, L.L., Zhou, H.S., Liu, X.L., Rtesunate induces SKM-1 cells apoptosis by inhibiting hyperactive beta-catenin signaling pathway. Int. J. Med. Sci. 12 (2015), 524–529.
187. Hui, H.Y., Wu, N., Wu, M., Liu, Y., Xiao, S.X., Zhang, M.F., Dihydroartemisinin suppresses growth of squamous cell carcinoma A431 cells by targeting the Wnt/beta-catenin pathway. Anticancer Drugs 27 (2016), 99–105.
188. Xu, G., Zou, W.Q., Du, S.J., Wu, M.J., Xiang, T.X., Luo, Z.G., Mechanism of dihydroartemisinin-induced apoptosis in prostate cancer PC3 cells: an iTRAQ-based proteomic analysis. Life Sci. 157 (2016), 1–11.
189. Zhang, J., Guo, L., Zhou, X., Dong, F., Li, L., Cheng, Z., et al. Dihydroartemisinin induces endothelial cell anoikis through the activation of the JNK signaling pathway. Oncol Lett. 12 (2016), 1896–1900.
190. Button, R.W., Lin, F., Ercolano, E., Vincent, J.H., Hu, B., Hanemann, C.O., et al. Artesunate induces necrotic cell death in schwannoma cells. Cell. Death. Dis., 5, 2014, e1466.
191. Hu, W., Chen, S.S., Zhang, J.L., Lou, X.E., Zhou, H.J., Dihydroartemisinin induces autophagy by suppressing NF-kappaB activation. Cancer Lett. 343 (2014), 239–248.
192. Chen, S.S., Hu, W., Wang, Z., Lou, X.E., Zhou, H.J., p8 attenuates the apoptosis induced by dihydroartemisinin in cancer cells through promoting autophagy. Cancer Biol. Ther. 16 (2015), 770–779.
193. Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
194. Dixon, S.J., Patel, D.N., Welsch, M., Skouta, R., Lee, E.D., Hayano, M., et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife, 3, 2014, e02523.
195. Louandre, C., Ezzoukhry, Z., Godin, C., Barbare, J.C., Maziere, J.C., Chauffert, B., et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int. J. Cancer 133 (2013), 1732–1742.
196. Skouta, R., Dixon, S.J., Wang, J., Dunn, D.E., Orman, M., Shimada, K., et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136 (2014), 4551–4556.
197. Efferth, T., Koch, E., Complex interactions between phytochemicals: the multi-target therapeutic concept of phytotherapy. Curr. Drug Targets 12 (2011), 122–132.
198. Wöll, S.K., S.H, Greten, H.J., Efferth, T., Animal plant warfare and secondary metabolite evolution. Nat. Prod. Bioprospect 3 (2013), 1–7.
199. Chen, H.H., Zhou, H.J., Fang, X., Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol. Res. 48 (2003), 231–236.
200. Chen, H.H., Zhou, H.J., Wang, W.Q., Wu, G.D., Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother. Pharmacol. 53 (2004), 423–432.
201. Huan-huan, C., Li-Li, Y., Shang-Bin, L., Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell. Cancer Lett. 211 (2004), 163–173.
202. Anfosso, L., Efferth, T., Albini, A., Pfeffer, U., Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J. 6 (2006), 269–278.
203. Wu, X.H., Zhou, H.J., Lee, J., Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion. Anticancer Drugs 17 (2006), 839–848.
204. Zhou, H.J., Wang, W.Q., Wu, G.D., Lee, J., Li, A., Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul. Pharmacol. 47 (2007), 131–138.
205. Chen, H., Shi, L., Yang, X., Li, S., Guo, X., Pan, L., Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells. Int. J. Hematol. 92 (2010), 587–597.
206. Sertel, S., Eichhorn, T., Sieber, S., Sauer, A., Weiss, J., Plinkert, P.K., et al. Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem. Biol. Interact. 185 (2010), 42–52.
207. Wang, S.J., Sun, B., Cheng, Z.X., Zhou, H.X., Gao, Y., Kong, R., et al. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-kappaB pathway. Cancer Chemother. Pharmacol. 68 (2011), 1421–1430.
208. Dong, F., Zhou, X., Li, C., Yan, S., Deng, X., Cao, Z., et al. Dihydroartemisinin targets VEGFR2 via the NF-kappaB pathway in endothelial cells to inhibit angiogenesis. Cancer Biol. Ther. 15 (2014), 1479–1488.
209. Dong, F., Tian, H., Yan, S., Li, L., Dong, X., Wang, F., et al. Dihydroartemisinin inhibits endothelial cell proliferation through the suppression of the ERK signaling pathway. Int. J. Mol. Med. 35 (2015), 1381–1387.
210. Soomro, S., Langenberg, T., Mahringer, A., Konkimalla, V.B., Horwedel, C., Holenya, P., et al. Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties. J. Cell Mol. Med. 15 (2011), 1122–1135.
211. Saeed, M.E., Kadioglu, O., Seo, E.J., Greten, H.J., Brenk, R., Efferth, T., Quantitative structure-activity relationship and molecular docking of artemisinin derivatives to vascular endothelial growth factor receptor 1. Anticancer Res. 35 (2015), 1929–1934.
212. Li, L.N., Zhang, H.D., Yuan, S.J., Yang, D.X., Wang, L., Sun, Z.X., Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. Eur. J. Pharmacol. 588 (2008), 1–8.
213. Konkimalla, V.B., Blunder, M., Korn, B., Soomro, S.A., Jansen, H., Chang, W., et al. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide 19 (2008), 184–191.
214. Konkimalla, V.B., McCubrey, J.A., Efferth, T., The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells. Curr. Cancer Drug Targets 9 (2009), 72–80.
215. Lee, J., Zhang, G., Wu, X., Xu, F., Zhou, J., Zhang, X., Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-kappaB modulation. J. Cancer Res. Clin. Oncol. 138 (2012), 2095–2102.
216. Huang, C., Ba, Q., Yue, Q., Li, J., Chu, R., Wang, H., Artemisinin rewires the protein interaction network in cancer cells: network analysis, pathway identification, and target prediction. Mol. Biosyst. 9 (2013), 3091–3100.
217. Tan, W.Q., Chen, G., Jia, B., Ye, M., Artemisinin inhibits neuroblastoma proliferation through activation of AHP-activated protein kinase (AMPK) signaling. Pharmazie 69 (2014), 468–472.
218. Sertel, S., Eichhorn, T., Simon, C.H., Plinkert, P.K., Johnson, S.W., Efferth, T., Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. Molecules 15 (2010), 2886–2910.
219. Kim, H.G., Yang, J.H., Han, E.H., Choi, J.H., Khanal, T., Jeong, M.H., et al. Inhibitory effect of dihydroartemisinin against phorbol ester-induced cyclooxygenase-2 expression in macrophages. Food Chem. Toxicol. 56 (2013), 93–99.
220. Hwang, Y.P., Yun, H.J., Kim, H.G., Han, E.H., Lee, G.W., Jeong, H.G., Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. Biochem. Pharmacol. 79 (2010), 1714–1726.
221. Rasheed, S.A., Efferth, T., Asangani, I.A., Allgayer, H., First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int. J. Cancer 127 (2010), 1475–1485.
222. Fujita, T., Felix, K., Pinkaew, D., Hutadilok-Towatana, N., Liu, Z., Fujise, K., Human fortilin is a molecular target of dihydroartemisinin. FEBS Lett. 582 (2008), 1055–1060.
223. Liu, L.K., Wu, H.F., Guo, Z.R., Chen, X.J., Yang, D., Shu, Y.Q., et al. Targeted efficacy of dihydroartemisinin for translationally controlled protein expression in a lung cancer model. Asian Pac. J. Cancer Prev. 15 (2014), 2511–2515.
224. Kobayashi, D., Hirayama, M., Komohara, Y., Mizuguchi, S., Wilson Morifuji, M., Ihn, H., et al. Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors. J. Biol. Chem. 289 (2014), 26314–26326.
225. Zeng, Q.P., Zhang, P.Z., Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. Nitric Oxide 24 (2011), 110–112.
226. Zhao, Y.G., Wang, Y., Guo, Z., Gu, A.D., Dan, H.C., Baldwin, A.S., et al. Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. J. Immunol. 189 (2012), 4417–4425.
227. Jiang, J., Geng, G., Yu, X., Liu, H., Gao, J., An, H., et al. Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-kappaB/GLUT1 axis. Oncotarget 7 (2016), 87271–87283.
228. Zhang, L., Qian, H., Sha, M., Luan, Z., Lin, M., Yuan, D., et al. Downregulation of HOTAIR expression mediated anti-Metastatic effect of artesunate on cervical cancer by inhibiting COX-2 expression. PLoS One, 11, 2016, e0164838.
229. Bhisutthibhan, J., Pan, X.Q., Hossler, P.A., Walker, D.J., Yowell, C.A., Carlton, J., et al. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J. Biol. Chem. 273 (1998), 16192–16198.
230. Bhisutthibhan, J., Philbert, M.A., Fujioka, H., Aikawa, M., Meshnick, S.R., The Plasmodium falciparum translationally controlled tumor protein: subcellular localization and calcium binding. Eur. J. Cell Biol. 78 (1999), 665–670.
231. Eichhorn, T., Winter, D., Buchele, B., Dirdjaja, N., Frank, M., Lehmann, W.D., et al. Molecular interaction of artemisinin with translationally controlled tumor protein (TCTP) of Plasmodium falciparum. Biochem. Pharmacol. 85 (2013), 38–45.
232. Hinojosa-Moya, J., Xoconostle-Cazares, B., Piedra-Ibarra, E., Mendez-Tenorio, A., Lucas, W.J., Ruiz-Medrano, R., Phylogenetic and structural analysis of translationally controlled tumor proteins. J. Mol. Evol. 66 (2008), 472–483.
233. Telerman, A., Amson, R., The molecular programme of tumour reversion: the steps beyond malignant transformation. Nat. Rev. Cancer 9 (2009), 206–216.
234. Amson, R., Pece, S., Marine, J.C., Di fiore PP, telerman A. TPT1/TCTP-regulated pathways in phenotypic reprogramming. Trends Cell Biol. 23 (2013), 37–46.
235. Eichhorn, T., Schloissnig, S., Hahn, B., Wendler, A., Mertens, R., Lehmann, W.D., et al. Bioinformatic and experimental fishing for artemisinin-interacting proteins from human nasopharyngeal cancer cells. Mol. Biosyst. 8 (2012), 1311–1318.
236. Huang, M.E., Ye, Y.C., Chen, S.R., Chai, J.R., Lu, J.X., Zhoa, L., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988), 567–572.
237. Degos, L., Chomienne, C., Daniel, M.T., Berger, R., Dombret, H., Fenaux P, et al.v Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet 336 (1990), 1440–1441.
238. Efferth, T., Kaina, B., Toxicity of the antimalarial artemisinin and its dervatives. Crit. Rev. Toxicol. 40 (2010), 405–421.
239. Rutteman, G.R., Erich, S.A., Mol, J.A., Spee, B., Grinwis, G.C., Fleckenstein, L., et al. Safety and efficacy field study of artesunate for dogs with non-resectable tumours. Anticancer Res. 33 (2013), 1819–1827.
240. Hosoya, K., Couto, C.G., London, C.A., Kisseberth, W.C., Phelps, M.A., Dalton, J.T., Comparison of high-dose intermittent and low-dose continuous oral artemisinin in dogs with naturally occurring tumors. J. Am. Anim. Hosp. Assoc. 50 (2014), 390–395.
241. Breuer, E., Efferth, T., Treatment of iron-Loaded veterinary sarcoma by artemisia annua. Nat. Prod. Bioprospect. 4 (2014), 113–118.
242. Efferth, T., Herrmann, F., Tahrani, A., Wink, M., Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin. Phytomedicine 18 (2011), 959–969.
243. Breakthroughs for Preventing and Surviving Cancer. Rowen, R.J., (eds.), 2002, Second Opinion Publishing Inc, Atlanta, Georgia.
244. Singh, N.P., Verma, K.B., Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch. Oncol. 10 (2002), 279–280.
245. Berger, T.G., Dieckmann, D., Efferth, T., Schultz, E.S., Funk, J.O., Baur, A., et al. Artesunate in the treatment of metastatic uveal melanoma? First experiences. Oncol. Rep. 14 (2005), 1599–1603.
246. Michaelsen, F.-W.S., Schwarzkopf, M.E.M., Efferth, J., Activity of Artemisia annua and artemisinin derivaitives in prostate carcinoma. Phytomedicine 22 (2015), 1223–1231.
247. Efferth T, S.U., Krishna, S., Schmiedek, P., Wenz, F., Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature. Arch. Toxicol., 2016.
248. Uhl, M., Schwab, S., Efferth, T., Fatal liver and bone marrow toxicity by combination treatment of dichloroacetate and artesunate in a glioblastoma multiforme patient: case report and review of the literature. Front. Oncol., 6, 2016, 204.
249. Zhang, Z.Y., Yu, S.Q., Miao, L.Y., Huang, X.Y., Zhang, X.P., Zhu, Y.P., et al. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao 6 (2008), 134–138.
250. Jansen, F.H., Adoubi, I., C.K, J., DEC, T., Jansen, N., Tschulakow, A., et al. First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. Anticancer Res. 31 (2011), 4417–4422.
251. Krishna, S., Ganapathi, S., Ster, I.C., Saeed, M.E., Cowan, M., Finlayson, C., et al. A randomised, double blind, placebo-Controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine 2 (2015), 82–90.
252. Ericsson, T., Sundell, J., Torkelsson, A., Hoffmann, K.J., Ashton, M., Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies. Xenobiotica 44 (2014), 615–626.
253. Veerappan, A., Eichhorn, T., Zeino, M., Efferth, T., Schneider, D., Differential interactions of the broad spectrum drugs artemisinin, dihydroartemisinin and artesunate with serum albumin. Phytomedicine 20 (2013), 969–974.
254. Konig, M., von Hagens, C., Hoth, S., Baumann, I., Walter-Sack, I., Edler, L., et al. Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study. Cancer Chemother. Pharmacol. 77 (2016), 413–427.
255. Zhou, Y., Li, W., Xiao, Y., Profiling of multiple targets of artemisinin activated by hemin in cancer cell proteome. ACS Chem. Biol. 11 (2016), 882–888.
256. Ma, H., Yao, Q., Zhang, A.M., Lin, S., Wang, X.X., Wu, L., et al. The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model. Molecules 16 (2011), 10556–10569.
257. Jeong da, E., Song, H.J., Lim, S., Lee, S.J., Lim, J.E., Nam, D.H., et al. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget 6 (2015), 33046–33064.
258. Lu, Y.Y., Chen, T.S., Qu, J.L., Pan, W.L., Sun, L., Wei, X.B., Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. J. Biomed. Sci., 16, 2009, 16.
259. Zhang, P., Luo, H.S., Li, M., Tan, S.Y., Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2. Oncol. Targets Ther. 8 (2015), 845–854.